anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Hemophilia is associated with osteoporosis and increased prevalence of low bone mineral density (BMD). Soucek et al. reported sarcopenia and low trabecular BMD at the radius in the boys with hemophilia by CT.The severity of hemophilic arthropathy associated with lower BMD, muscle atrophy and obesity has been shown by some studies.

This is a single-center, cross-sectional, observational study. All participants will sign informed consent that fully disclosed the risks and benefits of study participation. The study will be performed at the Hemophilia Care and Research Center. Sixty adult patients (age ≥ 20) with hemophilia and 20 healthy subjects will be enrolled for scanning of the lean tissue, appendicular skeletal muscle mass (ASM), fat mass, lumbar spine and hip BMD by dual-energy X-ray absorptiometry (DXA) and assess serum vitamin D level. We will collect other clinically relevant information, including age, body mass index (BMI), hemophilia type and severity, inhibitor titer, Pettersson score by x-ray, HJHS, handgrip strength, history of HCV or HIV infection and history of fracture.
* The dosage of ZUBSOLV from Day 3 onwards should be progressively adjusted in increments/decrements of 2.9 mg/0.71 mg or lower of buprenorphine/naloxone to a level that holds the patient in treatment and suppresses opioid withdrawal signs and symptoms.
  * After treatment induction and stabilization, the maintenance dose of ZUBSOLV is generally in the range of 2.9 mg/0.71 mg buprenorphine/naloxone to 17.2 mg/4.2 mg buprenorphine/naloxone per day depending on the individual patient and clinical response. The recommended target dosage of ZUBSOLV during maintenance is 11.4 mg/2.9 mg as a single daily dose. Dosages higher than 17.2 mg/4.2 mg buprenorphine/naloxone have not been demonstrated to provide any clinical advantage.
  * When determining the prescription quantity for unsupervised administration, consider the patient’s level of stability, the security of his or her home situation, and other factors likely to affect the ability to manage supplies of take-home medication. 
  * There is no maximum recommended duration of maintenance treatment. Patients may require treatment indefinitely and should continue for as long as patients are benefiting and the use of ZUBSOLV contributes to the intended treatment goals.
INTRODUCTION: Patients suffering lumbosacral radicular pain report radiating pain in one or more lumbar or sacral dermatomes. In the general population, low back pain with leg pain extending below the knee has an annual prevalence that varies from 9.9% to 25%.
METHODS: The literature on the diagnosis and treatment of lumbosacral radicular pain was reviewed and summarized.
RESULTS: Although a patient's history, the pain distribution pattern, and clinical examination may yield a presumptive diagnosis of lumbosacral radicular pain, additional clinical tests may be required. Medical imaging studies can demonstrate or exclude specific underlying pathologies and identify nerve root irritation, while selective diagnostic nerve root blocks can be used to confirm the affected level(s). In subacute lumbosacral radicular pain, transforaminal corticosteroid administration provides short-term pain relief and improves mobility. In chronic lumbosacral radicular pain, pulsed radiofrequency (PRF) treatment adjacent to the spinal ganglion (DRG) can provide pain relief for a longer period in well-selected patients. In cases of refractory pain, epidural adhesiolysis and spinal cord stimulation can be considered in experienced centers.
CONCLUSIONS: The diagnosis of lumbosacral radicular pain is based on a combination of history, clinical examination, and additional investigations. Epidural steroids can be considered for subacute lumbosacral radicular pain. In chronic lumbosacral radicular pain, PRF adjacent to the DRG is recommended. SCS and epidural adhesiolysis can be considered for cases of refractory pain in specialized centers.
1. Use of methoxymorpholino doxorubicin (MNmX) of formula in the preparation of a medicament formulated for intrahepatic administration through hepatic artery in the treatment of a human liver tumor. 2. Use according to claim 1, wherein the liver tumor is a tumor primarily confined to the liver. 3. Use according to claim 2, wherein the tumor primarily confined to the liver is a hepatocellular carcinoma (HCC) or a cholangiocarcinoma. 4. Use according to claim 1, wherein the tumor is a liver metastasis. 5. Use according to any one of the preceding claims, wherein MMDX is administered as an infusion of from about 15 minutes to about 30 minutes every 4 weeks. 6. Use according to any of claims 1-4, wherein MMDX is administered as a 5-10 minute bolus every 8 weeks. 7. Use according to any one of the preceding claims, wherein MMDX is administered with an agent, which remains selectively in a liver tumor after its injection through the hepatic artery. 8. Use according to claim 7, wherein the agent is iodized oil. 9. Use according to any of the preceding claims, wherein MMDX is administered in a dose ranging from about 100 mcg/m<2> to about 1000 mcg/m<2>. 10. Use according to claim 9, wherein MMDX is administered in a dose ranging from about 100 mcg/m<2> to about 800 mcg/m<2>. 11. Use according to claim 11, wherein the dose is 200 mcg/m<2>. 12. A pharmaceutical composition, which comprises as an active principle MMDX and a pharmaceutically acceptable agent which remains selectively in a liver tumor after its injection through the hepatic artery. 13. Use according to claim 12, wherein the agent is iodized oil. 14. Use of a pharmaceutical composition according to claim 12 or 13 for the treatment of a liver tumor. 15. Use of a pharmaceutical composition, which comprises as an active principle MMDX and a pharmaceutically acceptable agent that remains selectively in a liver tumor after its injection through the hepatic artery, for the preparation of a medicament formulated for intrahepatic administration in the treatment of a human liver tumor. 16. A pharmaceutical composition according to claim 13, wherein the agent is iodized oil.
BACKGROUND: Low back pain is one of the most frequent medical problems caused by different factors. It is important to evaluate low back pain by choosing the best suited tool for the specific spine condition and pain severity. The Spine Functional Index (SFI) is a relatively new physical functioning-related questionnaire that can be used to assess different aspects of daily activities and movements. The purpose of this study was to cross-culturally adapt the SFI for the Lithuanian language and to determine its psychometric properties of validity, reliability, construct stability, internal consistency and factor structure.
METHODS: The study was designed as a two-stage observational study. Double forward and backward translations of SFI were performed for cultural adaptation for the Lithuanian language. For evaluation of psychometric properties, 125 participants with non-specific low back pain (duration of symptoms ≥ 6 weeks) rated their pain using Numeric Rating Scale, completed the Lithuanian version of SFI and Oswestry Disability Index. In 3 to 7 days all participants completed Lithuanian version SFI for the second time. The full sample was employed to determine internal consistency, test-retest reliability, construct stability, measurement error, construct validity and factor structure.
RESULTS: There was good internal consistency and reliability with Lithuanian version of SFI as Cronbach's α = 0.92 and r = 0.82. Spearman-Brown coefficient was 0.97 representing good construct stability. Measurement error from standard error of the mean (SEM) was 6.96, from Minimal Detectable Change (MDC) was 16.24. Construct validity between the Lithuanian version of SFI and Oswestry Disability Index was excellent (ρ = 0.83), and good between the SFI and Numeric Rating Scale (ρ = 0.55). The factor analysis demonstrated a one-factor solution explaining 35.04% of total variance.
CONCLUSION: Lithuanian version of SFI is a new reliable and valid instrument for functional evaluation of back pain in Lithuanian speaking patients.
The invention relates to an external application traditional Chinese herbal preparation for curing children cough. The current western medicines for curing children cough mainly adopt antibiotics, hormone and antiallergic reaction medicine to treat, but the side reaction and the side effects are obvious, the internal organs and vessels of the human body can be damaged after long-term repeatedly use of large dosage and intravenous administration, particularly, the drug resistance of certain microorganisms to the medicine can be caused to generate, and even the production of super bacteria is facilitated. The oral traditional Chinese medicines, the western medicines and the traditional Chinese herbal preparation injection are not easy to be accepted by children. The medicine which is used by the method belongs to a formula for relieving superficies syndrome with pungent, warm and cool natured drugs, so the preparation has dual natures, enters the veins of lung, spleen, kidney and the like, and has the functions of relieving cough, reducing sputum, preventing asthma, relieving exterior syndrome and dispelling wind heat. Medicine patches are just applied on acupuncture points (dingchuan, dashu, fengmen, feishu and other acupuncture points) of the two sides and among the acupuncture points. The patches are changed every 24h with one to three patches. The patches can be separately applied, and also can be simultaneously used with the traditional Chinese medicines or the western medicines, so the treatment course can be shortened.
The patients will not receive any additional drugs preoperatively. 3ml of a 0.9% NaCl Solution (NaCl B. Braun Inf Lös 0.9 % 250ml Ecoflac plus®) will be administered at approx. 8.00 a.m. on the first postoperative day by the investigators.
BACKGROUND: Postoperative use of oral prednisone to augment the effect of multimodal pain regimens after total knee arthroplasty (TKA) has increased in popularity. However, data on the risks of its utilization, especially as it relates to infection, have been lacking. We tested the null hypothesis that perioperative prednisone use is not associated with the incidence of surgical and medical complications after TKA.
METHODS: Using a national administrative claims database, we identified 949,555 patients undergoing primary TKA. We excluded patients who filled oral prednisone prescriptions within 90 days prior to surgery or between 90 and 364 days after surgery. Patients who had acute prednisone use were defined as those who filled prednisone prescriptions only within 30 days after surgery. Outcomes consisted of surgical and medical complications after TKA. Multivariable logistic regression models were used to evaluate the association between acute prednisone use and complications, adjusting for age, sex, region, insurance plan, and Elixhauser comorbidities.
RESULTS: Patients in the acute prednisone cohort had greater adjusted odds of subsequent manipulation under anesthesia (adjusted odds ratio [OR] = 1.23 [95% confidence interval {CI}: 1.09 to 1.38]; P < .001) and lysis of adhesions (adjusted OR = 1.58 [95% CI: 1.02 to 2.33]; P = .03) compared to patients who did not have acute prednisone use. Patients who had acute prednisone use also had greater adjusted odds of acute kidney injury (adjusted OR = 1.47 [95% CI: 1.25 to 1.71]; P < .001) and pneumonia (adjusted OR = 4.04 [95% CI: 3.53 to 4.59]; P < .001). There was no increased incidence of infection.
CONCLUSIONS: Prednisone use shortly following TKA may be associated with a higher incidence of certain surgical and medical complications, but without increased risk for infection. However, given these risks, the optimal patient profile for postoperative prednisone use remains to be defined.
The invention relates to a composition in an aqueous gel state, a medicament consisting of said composition and a method for the production of said composition. The invention more specifically relates to a composition for topical application of an active ingredient which is hardly soluble or non-soluble in water, said composition comprising at least 50 wt. % purified water. The composition also comprises at least one humectant, a surfactant and a gel agent. The composition is provided for the production of an antiherpetic medicament containing 9[(2-hydroxyethoxy)]methylguanine, known by the name of aciclovir. The invention also relates to a method for the production of a composition in an aqueous gel state, characterized by: a pre-mixing step wherein the active ingredient is incorporated into a mixing agent in order to obtain a first fluid and homogeneous phase;  a step in which the active ingredient is dispersed, wherein a surfactant and/or humectant is incorporated into the first phase, in order to obtain a second and fluid homogeneous phase; a gelation phase in which said second phase is incorporated into an aqueous suspension of the gel agent.
Chest physiotherapy with an Aerobika oPEP device daily for 15 minutes each day for 1 month. Instruction by a physiotherapist as to proper technique will be given at the beginning of the study.
For purposes of analysis, 2 patient populations are defined. One population consists of those babies who did not develop severe hyperbilirubinemia (TSB \<9 mg/dL) during the first 36 hours of age. This population is referred to as the untreated population of screened but not randomized patients. The second population of babies was defined as those infants who develop severe hyperbilirubinemia. These infants were randomized to treatment with either stannsoporfin or the sham injection and will be the focus of the efficacy and safety analysis. This population was referred to as the treated population.

The treated population was used for the efficacy and safety analysis. These infants were randomized to either stannsoporfin or the sham injection treatment group.
Clarithromycin and its active metabolite 14-hydroxy clarithromycin are excreted in human milk. Serum and milk samples were obtained after 3 days of treatment, at steady state, from one published study of 12 lactating women who were taking clarithromycin 250 mg orally twice daily. Based on the limited data from this study, and assuming milk consumption of 150 mL/kg/day, an exclusively human milk fed infant would receive an estimated average of 136 mcg/kg/day of clarithromycin and its active metabolite, with this maternal dosage regimen. This is less than 2% of the maternal weight-adjusted dose (7.8 mg/kg/day, based on the average maternal weight of 64 kg), and less than 1% of the pediatric dose (15 mg/kg/day) for children greater than 6 months of age. 

  


A prospective observational study of 55 breastfed infants of mothers taking a macrolide antibiotic (6 were exposed to clarithromycin) were compared to 36 breastfed infants of mothers taking amoxicillin. Adverse reactions were comparable in both groups. Adverse reactions occurred in 12.7% of infants exposed to macrolides and included rash, diarrhea, loss of appetite, and somnolence.

  


Caution should be exercised when clarithromycin is administered to nursing women. The development and health benefits of human milk feeding should be considered along with the mother's clinical need for clarithromycin and any potential adverse effects on the human milk fed child from the drug or from the underlying maternal condition.
Single oral doses of 3 g/kg benazepril were associated with significant lethality in mice. Rats, however, tolerated single oral doses of up to 6 g/kg. Reduced activity was seen at 1 g/kg in mice and at 5 g/kg in rats. Human overdoses of benazepril have not been reported, but the most common manifestation of human benazepril overdosage is likely to be hypotension.

Laboratory determinations of serum levels of benazepril and its metabolites are not widely available, and such determinations have, in any event, no established role in the management of benazepril overdose.

No data are available to suggest physiological maneuvers (e.g., maneuvers to change the pH of the urine) that might accelerate elimination of benazepril and its metabolites. Benazepril is only slightly dialyzable, but dialysis might be considered in overdosed patients with severely impaired renal function (see WARNINGS).

Angiotensin II could presumably serve as a specific antagonist-antidote in the setting of benazepril overdose, but angiotensin II is essentially unavailable outside of scattered research facilities. Because the hypotensive effect of benazepril is achieved through vasodilation and effective hypovolemia, it is reasonable to treat benazepril overdose by infusion of normal saline solution.
The invention provides a diagnosis and treatment auxiliary device, a working method and a working program thereof, and a diagnosis and treatment auxiliary system, wherein the future illness state of a patient to be diagnosed can be easily predicted. An acquisition unit (47) acquires a comparison case as clinical data having the same clinical route as a patient to be treated from an electronic medical record DB (14). A display pattern specifying unit (48) assigns each comparative case to each group by comparing the treatment period of each comparative case with the condition. Display colors are preset in each group. A screen display control unit (49) generates a graph comparison display screen (21) on which a line graph (70) showing the time-series change of the examination value of a patient to be diagnosed and a plurality of line graphs (71) showing the time-series change of the examination value of each comparison case are superimposed and displayed. The broken line graph (71) is color-divided according to the display color determined by the display mode determination unit (48).
The SpO2 averaging time will be set to 10 s for the next 12 hours. All elements of care will be as routinely used, except the changing of the averaging time setting.
BACKGROUND: Tussis, which increases the incidence of airway spasm, aspiration, nausea, and vomiting, is a common complication faced during upper gastrointestinal (GI) endoscopy. However, sedatives and analgesics exhibit inhibitory actions against airway reflexes to different degrees. Our assumption is a combination of propofol and small doses of sufentanil, esketamine, or lidocaine, especially the combination of propofol and esketamine, might reduce tussis incidence.
METHOD: The study will be performed as a randomised controlled three-blind, two-centre trial. Patients undergoing upper GI endoscopy, ≥ 18 years old, with American Society of Anesthesiologists (ASA) classification I-III will be randomised to four groups: P group (single administration of propofol), P + S group (administration of propofol and sufentanil in combination), P + K group (administration of propofol and esketamine in combination), and P + L group (administration of propofol and lidocaine in combination) (N = 100 per group). The primary endpoints include the frequency of tussis, nausea and vomiting, and/or body movements observed at the insertion of the endoscope into the pharyngeal cavity or within 5 min of endoscope insertion. Secondary outcomes are recovery assessment, patients' and endoscopists' satisfaction with the procedure, MMSE scores, MET scores, sleep condition, and the number of sedation-related events. Data on sedation-related events are collected by recording of vital signs. Satisfaction parameters and mental states are collected by means of questionnaires and evaluation scales before and after the procedure and on different following days.
DISCUSSION: Esketamine can reduce tussis occurrence with good tolerability and relax the bronchus and also provides high clearance rates and low possibility of adverse reactions. We aim to demonstrate that the combination of esketamine with propofol for sedation in patients subjected to upper GI procedure is nevertheless superior to only administration of propofol or a combination of propofol with other anaesthetics, such as opioids or lidocaine.
TRIAL REGISTRATION: ClinicalTrials.gov. NCT05497492 , Registered 09 August 2022.
Sleep disordered breathing (SDB) is a common disorder with an estimated prevalence in the elderly ranging from 30-80%. The relevance of this high frequency in late life is emerging, as recent evidence suggests that SDB may be associated with the development of mild cognitive impairment and dementia. Alzheimer's disease (AD) is the most common form of dementia and affects nearly 45% of the population older than 85. Hippocampal atrophy and glucose hypometabolism, as well as changes in cerebrospinal fluid (CSF) levels of amyloid beta-42 (Aβ42), phosphorylated-tau (P-Tau) and total-tau (T-Tau), have been shown to be useful in predicting future decline in cognitively normal older adults, which suggests that AD pathology is detectable prior to cognitive impairment in at-risk subjects. This "presymptomatic phase", in which tissue damage is minimal and whose detection precedes clinical symptoms, is an ideal stage for risk factor analysis and intervention trials. Our preliminary data show, for the first time in cognitively-normal elderly, that the severity of SDB (as measured by respiratory events with 4% desaturation, Apnea Hypopnea Index 4% \[AHI4%\]) is associated with the increase of CSF P-Tau and T-Tau, a decrease in glucose uptake (measured by FDG-PET) in the medial temporal lobe, reduced hippocampal volume, and longitudinal memory decline. These findings raise the question as to whether AD tissue damage causes SDB in the elderly, or alternatively, if SDB acts as a risk factor for neurodegeneration. The proposed parent grant for this project conducted at the NYU Center for Brain Health (CBH), is a 5-year NIH-funded longitudinal study of 180 normal elderly (50-95 years), who will undergo complete baseline and 24 month follow-up evaluations. The exams include MR imaging: both structural and cerebral blood flow (CBF) using a novel NYU arterial spin labeling (ASL) protocol and regional brain vasoreactivity estimates after CO2 breathing (VR-CO2); as well as both plasma and CSF biomarkers. The present ancillary proposal, performed in collaboration with NYU's Sleep Disorders Center, will investigate: 1) SDB as a longitudinal predictor of changes in memory, levels of P-tau and T-Tau, hippocampal atrophy, and the blunted VR-CO2 response (all these effects of SDB were observed in cross-section in our pilot work); and 2) if these SDB related phenomena in normal elderly are susceptible to intervention with nasal continuous positive airway pressure (CPAP) in moderate-to-severe SDB subjects. This study has the potential to identify: 1) a highly prevalent AD-related mechanism by which SDB contributes to cognitive decline; 2) the alternative hypothesis, the presence of biomarker features of AD as risks factors for SDB; and 3) that the treatment of SDB with CPAP improves cognition through an AD-related pathway in the elderly.
Pomalidomide will be supplied as 1.0 mg, 2.0 mg, 3.0 mg and 4.0 mg capsules for oral administration. The principal investigator will determine whether intrapatient dose escalation is indicated based on the response of the patient's bleeding during the first 30 days of therapy. If dose escalation is indicated, pomalidomide will be increased by 1 mg/month at the investigator's discretion to a maximal dose of 5 mg/day.